Robert Wenham, MD, MS, FACS, On Assessing FSHR-CAR-T Therapy in Ovarian Cancer

Video

The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.

“This is somewhat unique in that we're delivering the cells directly into the peritoneal cavity... We don't really know if intraperitoneal is necessary. There's lots of reasons you could theorize while intraperitoneal may be good, because that's where most of theovarian cancer is... There is also some preclinical data suggesting that that may be the preferred route as well, and we will find out.”

A phase 1 study (NCT05316129) being conducted at Moffitt Cancer Center, in Tampa, Florida, is evaluating Anixa Biosciences’ chimeric endocrine receptor T-cell (CER-T) therapy targeting follicle stimulating hormone receptor (FSHR) for the potential treatment of ovarian cancer.

The dose-escalation study will determine the maximum tolerated dose of the CER-T therapy and will evaluate its safety profile in up to 48 participants delivered either intravenously or through intraperitoneal injection. The first patient with ovarian cancer was dosed in August 2022.

CGTLive spoke with the trial’s principal investigator Robert Wenham, MD, MS, FACS. Wenham serves as the chair of gynecologic oncology at Moffitt Cancer Center.Wenham discussed enrollment, protocols, and outcomes of the trial. He stressed the interdisciplinary collaboration available at Moffitt aswell as the value of his colleagues’ previous experiences and research.

REFERENCE
Anixa Biosciences announces treatment of first patient in its ovarian cancer CAR-T clinical trial. News release. August 15, 2022. https://ir.anixa.com/press-releases/detail/999/anixa-biosciences-announces-treatment-of-first-patient-in
Recent Videos
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Michael Severino on In Vivo Gene Editing With RNA Gene Writers
Jacques Galipeau, MD, on Exponential Progress With Cell and Gene Therapy
Manali Kamdar, MD, on Liso-Cel's Ongoing Benefit in the Treatment Lanscape for LBCL
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Related Content
© 2025 MJH Life Sciences

All rights reserved.